腺基编辑有力抑制乙型肝炎的表面抗原表达并抑制乙型肝炎D病毒的释放
bioRxiv : the preprint server for biology
|February 12, 2026
概括
腺基编辑提供了一种新的策略,通过准其DNA储存器来破坏乙型肝炎病毒 (HBV) 复制. 这种方法显示出在体外和体内减少HBVDNA和HBsAg产生的显著潜力.
科学领域:
- 分子生物学分子生物学
- 病毒学 病毒学
- 基因编辑 基因编辑
背景情况:
- 需要新的抗病毒策略来消除肝脏内乙型肝炎病毒 (HBV) 的DNA储存,包括共闭圆形DNA (cccDNA) 和集成的HBVDNA.
- 基编辑被探索为一种潜在的方法,通过准重叠的HBs/聚合酶开放读取框架 (ORF) 来破坏HBV复制.
研究的目的:
- 评估腺基编辑 (ABE) 作为对抗HBV的治疗策略.
- 评估ABE在破坏HBV复制和减少病毒标记物的有效性,在体外和体内.
- 研究HBsORF编辑对D型肝炎病毒 (HDV) 释放的影响.
主要方法:
- 设计了一个腺基编辑器 (ABE) 和指导RNA (gRNA) 来引入HBs/聚合酶ORF的突变.
- 与HBV感染的人类肝细胞和细胞系 (HepG2-hNTCP,HepG2.2.15,PLC/PRF/5) 相同转移的ABE mRNA和gRNA.
- 利用脂质纳米颗粒 (LNPs) 在体内输送ABE和gRNA在HBV循环DNA转化和HBV感染的人类肝细胞小鼠中. 在基于细胞的模型中评估了HDV释放.
主要成果:
- 基编辑通过向ccccDNA和集成HBVDNA,显著降低了HBsAg的产生和HBV复制在体外.
- 单次LNP注射导致HBsAg在HBVcircle小鼠中无法检测到;两次注射在人类肝细胞基米小鼠中将血清HBsAg降低了90%.
- 在体内,HBV DNA复制被抑制,HBs ORF基编辑在体内明显抑制了HDV释放.
结论:
- 编辑HBsORF的腺基是一种有效的策略,可以损害HBV复制和HBsAg生产.
- 这种方法证明了HBV和HDV感染的治疗潜力.
- 基础编辑为开发针对持续性HBV感染的新型抗病毒疗法提供了一个有希望的途径.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
281
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Hepatic Portal System
6.3K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.3K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
250
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
250
RNA Editing
9.9K
RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...
9.9K
Hepatic Drug Excretion: Influencing Factors
603
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
603
Hepatic Drug Clearance: Role of Transporters
311
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
311


